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Abstract 
Over the last 5 years the UK has led the world in the introduction of new vaccines with substantial 
changes in the childhood vaccination schedules.  These have been both in response and in 
anticipation of changes in the epidemiology of illness and demonstrate the importance of public 
health screening and the notification of infectious diseases.  This review article briefly outlines the 
rationale and history behind these most recent developments and highlights potential changes on 
the horizon. 
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ROTAVIRUS 
Epidemiology. Rotavirus (RV) is the single most important cause of infectious diarrhoea in young 
children worldwide and is responsible for almost a half a million deaths each year. Mortality related 
to RV infections is almost exclusively in resource-poor countries. In wealthier societies without high 
uptake vaccine programmes the infection remains common and the accompanying morbidity results 
in much distress and suffering as well as significant healthcare and societal pressures and costs. In 
temperate regions, RV infection occurs in annual epidemics usually peaking in early spring. Almost all 
children will have encountered the disease at least once by the age of five and the majority before 
the age of two. The virus is transmitted via the faeco-oral route and is abundantly excreted in stool 
during and sometimes for several weeks after the resolution of clinical symptoms. As few as ten viral 
particles are sufficient to cause clinical disease in susceptible individuals, which makes reliable 
prevention of spread of the infection by hygiene measures effectively impossible.  
Vaccines. The early history of RV vaccines had a profound effect on their subsequent development 
and uptake. In the 1990s the first licensed oral RV vaccine (RotaShield® Wyeth) completed phase III 
trials and rapidly went into use in the USA. However after nine months post-marketing surveillance 
suggested clustering in incidence of intussusception (IS) particularly in the period following the first 
dose in vaccinated individuals, leading to the voluntary withdrawal of the vaccine from the market. 
Nearly ten years later in 2006, two new live oral vaccines were licensed in Europe, Rotarix 
(GlaxoSmithKline Biologicals) and RotaTeq (Merck & Co, Sanofi Pasteur-MSD). 
Rotarix is a monovalent attenuated human RV strain given to infants 6 – 24 weeks of age as two oral 
doses at least four weeks apart. The phase III trial in >63,000 children reported no increase in rates 
of IS, 85% effectiveness against hospital admissions and 85% against severe disease and up to 100% 
against very severe disease. An efficacy trial carried out in South Africa and Malawi reported 61.2% 
efficacy against severe disease and although it was lower in the more resource-poor Malawi (49.4% 
vs. South Africa 76.9%), the impact on mortality there was predicted to be higher due to higher 
burden of disease there.  
RotaTeq is a pentavalent vaccine combining human-bovine reassortant strains and is given to infants 
6–33 weeks of age as three oral doses at least 4 weeks apart. Pre-licensure studies in >69,000 
children also showed no increase in rates of IS, 74% protection against all RV gastroenteritis and 98% 
protection against severe disease with an almost 95% reduction in emergency room attendance and 
86% reduction in missed work days by parents of vaccinated children. Large efficacy trials in Asia and 
sub-Saharan Africa found 48.3% and 39.3% protection against severe disease. The consistent finding 
of reduced efficacy in countries with lower socio-economic status is still not clearly understood and 
is likely to be multi-factorial. Proposed contributing factors are higher rates of breastfeeding 
(containing higher titres of anti-rotavirus antibodies), oral polio vaccine use, higher prevalence of 
other viral and bacterial gut infections, malnutrition and other socio-economic factors. Nevertheless 
because of high RV mortality rates in these countries, it is here that the vaccines have the potential 
to prevent hundreds of thousands of diarrhoea-related deaths. 
Approaches to roll out. In 2009 the World Health Organization (WHO) - Strategic Advisory Group of 
Experts (SAGE) recommended that RV vaccine be introduced to all countries’ immunisation 
programmes. But the decision to implement this advice is influenced by each country’s healthcare 
system and burden of disease. In regions such as Western Europe that have low rates of mortality, 
inclusion has been gradual with only 7 countries currently giving RV vaccine routinely, although in 
most of the others the vaccines are also available privately – usually resulting in limited coverage 
and so few herd effects. Almost all mortality from RV occurs in the very poorest countries and the 
Global Alliance on Vaccines and Immunisation (GAVI) was set up with the aim of meeting the 
Millennium Development Goal 4 – reduction of childhood mortality. They have pledged to give 
financial support to help introduce childhood vaccines in a sustainable way, pooling demand to 
shape vaccine markets and helping fund vaccines though a co-payment process. By supporting the 
upfront cost of vaccine introduction, the hope is that resulting socio-economic and healthcare 
savings will facilitate ongoing use. GAVI has been able to secure RV vaccines at $5 per course 
compared to around €45 per dose on the open market. Eligible countries can then obtain them from 
GAVI from just $0.20 per dose.  Of the 81 countries now including rotavirus vaccines in their routine 
schedule (figure 1), 31 are supported by GAVI. 
  
Fig 1: Current Worldwide use of RV vaccine – data source World Health Organization  
 
Intussusception. Although both the large pre-licensure trials did not detect any increase in rates of 
IS, since the two current vaccines were introduced to widespread clinical use, national surveillance 
data from Australia, Mexico, Brazil and the USA have shown convincing evidence of an association 
for both of them at a rate of around 1 in 50-100,000. It remains unclear whether these represent 
additional cases or precipitation of cases that would otherwise have occurred later. The current 
position of the WHO Global Advisory Committee on Vaccine Safety (GACVS) is that “based on 
available evidence, the benefits of RV vaccination to all infants, without age restriction, would 
greatly exceed the risks, particularly in developing countries with moderate and high mortality from 
RV disease”. 
Implementation and impact. The UK introduced Rotarix into the routine childhood schedule in July 
2013 and rapidly achieved 98% first dose coverage. The first season after introduction saw estimated 
reductions of up to 150,000 general practice attendances, 35,700 ED attendances and 8,120 
admissions to hospital. A population case control study identified an increased risk of 
intussusception in the 1-7 days after vaccination with an estimated additional 21 cases following 
vaccination, all of whom were treated successfully. Experience in similar high income countries such 
as the USA, Australia, Israel, Belgium, Austria, Luxembourg and Finland which have introduced 
routine RV vaccination, shows it to be highly effective (90% prevention of hospital admission) and to 
result in large reductions in healthcare costs. In middle and lower income countries it has been 
shown to have profound effects on childhood mortality. In Mexico a 46% reduction in under five 
mortality due to gastroenteritis has been shown. Early post implementation data from the GAVI 
countries is also positive with reports of reductions in rates of hospitalisation by 50% and vaccine 
effectiveness estimated at 65%. 
There are many low cost high volume alternatives vaccines at varying stages of development. 
Notably India has developed its own, costing $1 per dose. Injectable inactivated vaccines are also in 
very early development and with proposed benefits such as increased heat stability, lack of 
association with IS and less vulnerability to environmental interference, they may ultimately prove 
to be an effective alternative approach. 
With the current vaccines now having been in use for ten years and with many millions of doses 
given, no new problems with serious side-effects or strain switching have materialised to date. In 
high income settings significant economic savings have been seen consistently while in low resource 
settings there have been significant reductions in mortality. With so many countries of the world 
now sparing their children from this disease, it will be of interest to observe how long it takes the 
rest to follow suit and introduce universal infant vaccination against RV. 
MENINGOCOCCUS  
Despite a substantial reduction of annual laboratory-confirmed cases of invasive meningococcal 
disease (IMD) in the UK over the past 15 years (2448 in 2000-2001 to 724 of 2014-2015, 
epidemiological year, July-June), IMD remains the leading infectious cause of death in early 
childhood and causes significant morbidity and mortality, especially in young infants where 5-10% of 
victims do not survive and up to 20% suffer from serious sequelae including limb loss and seizures 
while up to 57% suffer from cognitive impairments 
The burden of meningococcal disease is greatest in young children, with half of cases currently 
diagnosed in those less than 5 years of age.  This is therefore the population in greatest need of 
direct protection. Incidence rates are also somewhat higher in late adolescence and among the 
elderly than during the rest of adult life. The nasopharynx provides a stable ecological niche for 
meningococci and humans are the only known animal hosts. Eliminating carriage would therefore 
eliminate disease. Vaccination with conjugate vaccines against meningococcal disease has been 
shown to impact on carriage. However meningococcal carriage is rare in early childhood and 
commoner in adolescents and young adults; rates as high 55% have been reported in university 
students. 
Meningococcus can be divided into strains based on the characterisation of its polysaccharide 
capsule.  The relative rates of each group have risen and fallen over time with the emergence of 
strains with varying invasive potential (see below). 
Figure 2. Taken from PHE Health Protection Report Oct 2015 
 
Some of these declines can be partially explained through changing behaviours such as reduced 
smoking rates but fundamentally they remain driven by a poorly understood complex interaction 
between population immunity and meningococcal bacteria, which lead to the arrival and eventual 
disappearance of various clones with differing predisposition to cause disease. 
In 2015, the UK became the ﬁrst country in the world to have a comprehensive routine 
meningococcal vaccine programme targeting all of the main disease-causing capsular groups of N. 
meningitidis (A, B, C, W and Y). The meningococcal immunisation schedule against the different 
capsular groups targets both age groups and populations at highest risk of disease to provide direct 
protection and those with highest carriage rates to reduce transmission and confer indirect 
protection (herd immunity), approaches which are under continuous review by the UK Joint 
Committee on Vaccination and Immunisation (JCVI). 
Men C 
The glycoconjugate Men C was the first universal meningococcal vaccine to be introduced by the UK 
National Health Service (NHS) in 1999. The programme in infants, alongside a large catch up 
programme for all children and adolescents, was in response to a rapid rise in IMD cases caused by a 
single Men C clone (part of the ST-11 complex) which was associated with a high case fatality rate. 
This successfully controlled the outbreak and resulted in sustained population protection against 
Men C over the past 15 years with clear evidence of reduced rates of asymptomatic colonisation 
with this serogroup. The current Men C immunisation schedule not longer includes infants with 
doses only at 12 months and 13-14 years. The adolescent booster was added to secure enduring 
herd protection as the year 2000 catch up cohort aged and was supported by evidence that 
vaccination at this age was very immunogenic with good antibody persistence.  In 2015 this 
adolescent booster was changed from monovalent Men C to quadrivalent Men ACWY conjugate 
vaccine as discussed below. 
Men B  
In England, Men B is the main cause of IMD although prior to Men B vaccine introduction, there was 
a significant reduction in the absolute number of IMD caused by Men B, from 1614 cases in 
2000/2001 (epidemiological year, July to June) to 418 cases in 2014/2015(see figure 2).  After more 
than two decades of clinical development, a multi-component Men B (4CMenB) vaccine was licensed 
by the European Medicines Agency in early 2013, and in September 2015 a long awaited national 
infant vaccine programme against Men B was launched in the UK. The vaccine is included in the 
primary immunisation schedule at 2, 4 and 12 months of age. At present, there is no adolescent 
booster or catch-up programme. 
The Men B vaccine was difficult to develop; Men B capsular polysaccharide, unlike the other 
meningococcal groups is poorly immunogenic and identical saccharides are found on human foetal 
neural cell adhesion molecules (and are thus self antigens). Significant antigenic diversity among 
endemic Men B strains has complicated selection of subcapsular Men B antigens for vaccine 
development. The 4CMenB vaccine comprises four components; three are recombinant 
meningococcal surface antigens, the fourth an outer membrane vesicle (OMV) made by detergent 
extraction from a strain which caused an extended outbreak in New Zealand where this latter 
component was used as a stand-alone vaccine. The new Men B vaccine is predicted to cover 73–88% 
of Men B strains causing invasive disease in the UK with at least one antigen and due to its OMV 
component may also theoretically have some effect against other groups. 
The infant programme is expected to provide direct protection for vaccinated children but little or 
no indirect (herd) protection. Further work is being undertaken to assess the potential for an 
adolescent Men B programme that, like the Men C, (and hopefully Men W) immunisation 
programme, might induce direct and indirect protection. However improved methodology for 
carriage detection in large-scale vaccine trials will be needed to gather the information required. 
Men W  
Historically, Men W has been a rare cause of IMD in England and Wales, accounting for <5% of all 
laboratory-confirmed cases but more recently, this has changed (Figure 3).  
In 2000-2001 there was a Men W outbreak among people returning from the Hajj pilgrimage  
accounting for 127 of 2448 cases (5.2%) during this period. This outbreak was controlled by 
mandatory Men ACWY vaccination of all pilgrims entering Saudi Arabia; by 2008-2009, the 
percentage of IMD caused by Men W had returned to baseline (21 of 1164 cases, 1.8%). Since 2009–
2010, cases are again increasing, nearly doubling annually to 2015 (Figure 4) and associated with a 
case fatality rate (12%) which is significantly higher than that reported for Men B. This increase has 
extended across all age groups, including adolescents (15–19 year-olds) and infants and none have 
been epidemiologically linked to Hajj travel since mandatory vaccination of pilgrims. Genome testing 
of Men W IMD cases has shown they belong to cc11 strain; this strain is very similar to the one 
responsible for recent South American outbreaks, associated with a very high case fatality rate (31% 
in Chile). Worryingly in both countries, this strain has been associated with atypical presentations: a 
retrospective study of confirmed Men W cases in 2012, found a low frequency of meningeal signs 
but nearly 50% of patients presenting with gastroenterological symptoms. After fever, diarrhoea was 
the second most frequent symptom among deceased patients (55.6%) and statistically higher than 
survivors (26.8%).  
Following JCVI recommendations, the UK national outbreak response has been rapid introduction of 
an adolescent Men ACWY conjugate vaccine programme from August 2015 replacing the Men C only 
booster. In addition to providing direct protection against these capsular groups, it is expected that, 
by reducing carriage rates, other age groups may be protected indirectly over the coming years 
provided sufficiently high uptake rates can be reached.  
There are early reports of increasing Men W IMD rates in other European countries alongside novel 
genetic changes in the circulating invasive strain. Accordingly steps may soon be needed to control 
the spread of this problem elsewhere. 
Figure 3. Taken from Eurosurveillance Campbell et al 2015  
 
The Future 
Where meningococcal vaccines induce immune responses which reduce colonisation and 
transmission, adolescent immunisation may ultimately prove to be the most efficient and cost 
effective approach to controlling IMD, provided high coverage can be reliably achieved. While there 
is evidence in support of this approach with conjugate vaccines, more research is needed before it 
can be used for the newer protein antigen “Men B” vaccines. Careful epidemiological surveillance 
remains essential as meningococcal disease constantly changes. 
Influenza - the introduction of live attenuated influenza vaccine (LAIV) for healthy children 
Influenza is one of the main causes of hospital admissions and death due to respiratory 
illness.  It occurs in annual epidemics with different strains, often having undergone genetic drift, 
predominating each year in an un-predictable manner, meaning vaccines have to be reformulated 
for each new season. Children aged under 5 years (especially those aged under 2 years), pregnant 
women, people aged over 65 years and those with underlying medical conditions are especially 
prone to complications caused by influenza. The UK has recommended vaccination of at risk 
populations since the 1960s but has recently extended the indications to include otherwise healthy 
young children. 
Children spread influenza to healthy individuals more easily than adults, as the viral load in 
their secretions is both higher and excreted for longer periods of time. Thus, it is thought that 
seasonal influenza epidemics are driven in the community by infection of and among children. 
Preventing the disease in this age group with an effective immunization programme could have an 
enhanced public health impact by also reducing rates of infection in other age and risk groups. 
In 2012, after reviewing from a dynamic transmission model, the UK JCVI, recommended 
annual vaccination of healthy children from the age of two years with live attenuated influenza 
vaccine (LAIV).  Live cold adapted strains of influenza virus given by intranasal spray stimulate an 
immune response in the upper airways but are unable to replicate in the warmer lower respiratory 
tract.  The efficacy this vaccine in children is well documented in a series of randomized controlled 
trials versus placebo and inactivated injected flu vaccine (IIV). The vaccine is safe with the most 
common adverse reactions being mild transient nasal congestion or low grade temperature. 
However studies have found a higher rate of wheezing in very young children so in both Europe and 
the USA it is not recommended for children under 2 years old or for children and adolescents with 
severe asthma or active wheezing.  Children at high risk with contraindications to LAIV or under the 
age of 2 years are still recommended to receive IIV. 
Introduction was planned as a staged rollout.  During the first (2013/14) influenza season a 
single dose of LAIV was offered to all children aged two and three years and in seven pilot areas to 
primary school aged children of four to eleven years.  Vaccine uptake in the pre-school age children 
was 41.1% and in pilot areas 52.5%. Influenza activity was unusually low during this season and it 
was difficult to evaluate vaccine effectiveness (VE) fully. However although not statistically 
significant, there was a consistent decrease in measures of disease between pilot and non-pilot 
regions supporting of the continuation of the programme. 
During the second season of rollout (2014/15) all healthy two to four year old children were 
offered LAIV vaccination. The 2013/14 primary school pilot areas continued vaccination with new 
pilot areas now also offering the vaccine to secondary school age children.  In the preschool cohort 
uptake levels were 37.6%.  Rates were higher in the school based pilot areas, 56.8% and 49.8% in 
primary and secondary schools respectively than in areas using primary care or pharmacy-based 
delivery. During this season the flu activity was moderate. Although the dominant strain subtype 
(H3N2) was contained in the vaccine, it had undergone antigenic drift from the predicted strain, 
reducing VE. According to the end of season studies the overall adjusted VE in children was 17.5 % 
(95 % CI: -41.1 - 51.7) for influenza A and 19.1 % (95 % CI: -44.1 - 54.6) for influenza A (H3N2). 
During the third season (2015/16) LAIV roll out was extended from all children two to four 
years old to school years 1 and 2 (5-7 years).  In Northern Ireland and Scotland all primary school age 
children were offered vaccination.  Coverage again was again low in preschool children (34.3%) and 
higher in schools (53.7%).  The main circulating strain was A (HINI)pdmo9. In children, overall VE 
against laboratory-confirmed influenza was 57.6% (95% CI: 25.1–76) and 41.5% (95% CI: −8.5 to 
68.5) for the dominant influenza A(H1N1)pdm09.  Interestingly these findings are in contrast with 
the 2015/16 VE reports from the CDC in the USA where VE of only 3% (-49% – 37%) for LAIV was 
reported compared to 63% (52%-72%) for IIV. Recommendations to use LAIV there have been 
withdrawn in the 2016/17 season. The reasons for this disparity are as yet unknown but results from 
other countries using LAIV such as Finland and Canada have been concordant with UK experience. 
Over the first three seasons of use in the UK, LAIV has shown superior VE to IIV in children 
53.1% (95% CI: 31.4–67.9) vs 31.5% (95%CI: −50.4–68.8).  But despite mismatched years, limited roll 
out and coverage issues, there has been some evidence of the anticipated herd effects in other age 
groups, particularly in areas of high coverage such as Scotland and Northern Ireland.  In 2016/17 the 
programme will continue to extend, vaccinating those from 2 years old to school year 3 (7-8yrs) with 
a target of 40-65% coverage.  The models suggest that this public health strategy has the potential 
for drastic reductions in influenza transmission in the UK, not only protecting those vulnerable to 
severe complications of influenza but improving the health of the entire community. 
Pertussis 
Bordetella pertussis is the most common vaccine preventable disease, despite generally high vaccine 
uptake, with recent epidemics, for example, in USA in 2012, UK in 2012 and Argentina in 2011. 
Incidence of pertussis have been increasing in many countries over the past 30 years, trends that 
started prior to, and accelerated following, the switch from whole cell pertussis (wP) vaccine to 
acellular pertussis (aP) vaccine in many primary immunisation schedules. This was done in many 
countries in the 1990s-2000s due to significant local and systemic side effects rates of wP vaccine; 
continued use of which could have threatened public confidence in immunisation programmes in 
general and latterly to the unavailability of wP-containing combination vaccines. Reasons for this 
resurgence are thought to be a combination of better clinical case recognition especially in older age 
groups, better diagnosis especially with increased availability of reliable detection using PCR, patchy 
vaccine coverage in some areas and principally reduced duration of protection following aP 
vaccination compared to wP and both vaccine types compared to immunity following infection, 
leading to infection and transmission among previously vaccinated people. There is also evidence 
from research in non-human primates that wP vaccines may have a greater impact upon 
transmission of the infection than aP vaccines. Finally there is some evidence of emergence of 
vaccine escape mutants. A major effort is now needed to improve pertussis control tools. Possible 
strategies include adjuvanted vaccines, development of novel vaccine antigens including live 
attenuated vaccines and, in the meantime, improved strategies for deployment of existing vaccines. 
Aspects acellular pertussis (aP) vaccine- induced immunity  
aP vaccines contain only 1-5 pertussis antigens whereas wP vaccines contain the whole organism 
and so thousands of antigens which may broaden protection and also have adjuvant effects. 
Bordetella pertussis strains lacking pertactin, an antigen included in most aP vaccines, have been 
reported circulating in Europe, Australia, Japan and the USA. These strains may have a selective 
advantage in highly immunised populations.  
Observational studies suggest waning immunity following aP vaccination, with children up to 15 
times more likely to acquire pertussis 5 years, as compared to 1 year, following the 5th aP dose. 
Animal studies suggest that the reason for this is that aP induces a CD4+ T helper (Th) 2 dominated 
immune response, whereas wP vaccines and natural infection induce a mixed CD4+ Th1/ Th17 
response. These distinct types of immune response have been shown following aP and wP 
vaccination in mice, baboons and children. Observational studies also suggest that individuals 
primed with aP were 2 to 5 times more likely to develop pertussis subsequently compared to those 
primed with wP suggesting that the immunological character of the initial response may endure to 
an extent regardless of subsequent exposure to vaccine boosters or infection. 
Large clinical trials prior to the implementation of aP vaccine and a recent Cochrane review  have 
shown that aP vaccination is up to 85% effective in preventing pertussis disease; however it may not 
prevent asymptomatic, or mildly symptomatic infection. This has been shown in the baboon model 
of pertussis where those vaccinated with aP vaccine, although protected from severe disease, were 
not protected from infection and were able to transmit infection to others; whereas wP vaccinated 
baboons cleared infection twice as fast. This hypothesis is supported by observational data in 
humans showing that infection continues to circulate especially in some aP-vaccinated populations; 
and that epidemiological peaks following periods of low vaccination suggest that aP vaccination can 
effectively control numbers of severe cases of disease but total numbers of cases to a much lesser 
extent. 
Strategies to improve the effectiveness of B. pertussis vaccination  
A short term option is to give additional boosters with the current combined aP vaccines (DTaP/IPV: 
Diphtheria, Tetanus, acellular Pertussis, inactivated polio vaccine) to targeted populations such as 
pregnant women from 20 weeks gestation. The aim of vaccinating pregnant women is to reduce 
disease in infants who have the highest mortality from pertussis, by reducing disease in mothers 
thereby interrupting transmission to their infants and by protecting the infant with passive antibody 
transfer from the mother via the placenta and breast milk. This strategy has been shown to be highly 
effective at reducing infant deaths in the UK in case control studies. Mothers are recommended to 
have further doses in subsequent pregnancies and although problems with adverse reactions to 
repeated doses have not been reported this remains a theoretical concern. Other strategies that 
have been proposed and, in some cases, implemented but only with limited success include: single 
adolescent or single or regular adult booster doses of DTaP, vaccination campaigns in response to 
outbreaks, immunisation of family contacts around newborns (the so-called cocooning strategy) and 
the production of aP only pertussis vaccines for use where boosters of other antigens are not 
necessary. 
A longer term solution is the development of a 3rd generation of more effective vaccines to protect 
against disease and carriage and give longer lasting immunity to pertussis, without the side effects of 
wP vaccine. A less complex option might be to modify existing vaccines. Reducing the content of 
endotoxin in the wP vaccine to make it less reactogenic has been proposed. Adapting aP vaccines by 
adding new antigens such as adenylate cyclase toxin, iron regulated proteins or the autotransporter 
BrKA are options as is adding to or replacing the aluminium adjuvant of existing aP vaccines with 
biological agents such as Toll- like receptor (TLR) agonists which can induce Th1 responses in mice. 
Following pre-clinical studies in mice showing Th1 responses, a live attenuated vaccine BPZE1 is in 
early phase clinical trials, being given intranasally (to target respiratory mucosal immunity) in adult 
volunteers. Both safety and efficacy would need to be shown in follow up studies. Vaccination with 
an aP nanoparticle vaccine composed of outer membrane vesicles given intranasally to mice 
produced a mixed Th1/Th2 response and good antibody response and has the potential to protect 
against both B. pertussis and parapertussis. 
Conclusions 
Widespread resurgences of pertussis despite high vaccination coverage are a serious problem. 
Current vaccination schedules, particularly those using aP vaccines, can result in ongoing circulation 
of pertussis despite high uptake and coverage. Development of new vaccines is challenging and will 
take time and demonstration of efficacy will be challenging in the absence of large unvaccinated 
populations. The WHO has recommended that countries using wP schedule should not switch to aP 
schedules for the time being while more research is done. These challenges are occurring on the 
background of severe supply shortages of pertussis containing vaccines in many areas. The one 
notable recent success has been the demonstration that fatal pertussis in early infancy can be 
reliably be prevented by immunisation of pregnant mothers with aP containing vaccines. This 
strategy is being adopted in many areas where significant numbers of infant cases are occurring. 
However, while it can prevent the worst cases and deaths, it will do little or nothing to reduce the 
broader circulation of pertussis in the community and so the risks remain. 
Final conclusions 
Over the last 5 years the UK has led the world with several introductions and effective 
implementations of childhood (and maternal vaccinations) as both reactive and pre-emptive 
modification of the vaccine schedule to optimise protection.  With the clear successes of rotavirus 
and maternal pertussis vaccination programmes and early evidence of the impact of influenza and 
MenB programmes, the question becomes what next?  Both universal hepatitis B and varicella 
vaccines have been shown to be very effective when used in other countries and the UK will 
introduce the former into the primary schedule in 2017 and is re-evaluating the latter.  The 
importance of retaining high vaccination coverage can be seen with large UK measles outbreaks in 
2013 as a result of the MMR vaccine scare of the 1990s and early 2000s and recent similar and 
equally unfounded collapses in public confidence in the HPV vaccine programmes in Denmark and 
Ireland which will doubtless result in many unprevented cases of malignancy and genital warts in 
those countries in the future.  As public perception of the risks of infectious diseases fall, the 
paediatrican’s role as childrens’ vaccine advocates becomes ever more vital. 
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